New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.

ABSTRACT: The overall low-quality evidence concerning the clinical benefits of different antibiotic regimens for the treatment of infective endocarditis (IE), which has made it difficult to strongly support or reject any regimen of antibiotic therapy, has led to a discrepancy between the available guidelines and clinical practice. In this complex scenario, very recently published guidelines have attempted to fill this gap. Indeed, in recent years several antimicrobials have entered the market, including ceftobiprole, ceftaroline, and the long-acting lipoglycopeptides dalbavancin and oritavancin. Despite being approved for different indications, real-world data on their use for the treatment of IE, alone or in combination, has accumulated over time. Furthermore, an old antibiotic, fosfomycin, has gai

SUBMITTER: Oliva A 

PROVIDER: S-EPMC10743892 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature